Rimon Therapeutics Ltd. (Toronto, ON)

www.rimontherapeutics.com

Rimon Therapeutics Ltd. is the Theramer™ Company. Theramers™ (therapeutic polymers) are polymers that have drug-like activity, but can be marketed and regulated as devices. Rimon’s Theramers™ induce the development of new blood vessels, prevent the destruction of tissue, and kill bacteria without harming human cells. The company is engaging some of the world’s largest medical device companies about using these unique polymers to heal chronic wounds (e.g., bedsores and diabetic ulcers), treat heart disease, delay knee replacement, and prevent medical device-related infections. Preliminary results from the Company’s first, human clinical trial of its MI-Sorb™ Dressing for chronic wounds are very promising and represent a key milestone in the validation of Rimon’s unique, value proposition – drug-like margins and device timelines, together with the versatility of polymer chemistry.

"We are delighted that such an esteemed jury has recognized the hard work, achievements and future potential of Rimon Therapeutics. The clinical validation this year of our novel therapeutic polymer (Theramer) platform technology, the near-term product licensing opportunities generated with some of the world's largest medical device companies, and now recognition as one of Canada's leading Life Science companies, demonstrates Rimon's ability to advance a robust pipeline of products to commercialization", says Michael H. May, President of Rimon Therapeutics Ltd.

See: http://www.bionorth.ca/Top10/2006_2007_Finalists.html